Replagal Advisory Committee Meeting Possible By End Of The Year, TKT Says

FDA's Endocrinologic & Metabolic Drugs Advisory Committee may consider Transkaryotic Therapies' Fabry Disease treatment, Replagal (agalsidase alfa), before the end of the year, TKT said